SimBioSys Archives - Medical Design Sourcing

SimBioSys wins FDA nod for TumorSight precision medicine platform

SimBioSys announced that it received FDA 510(k) clearance for its TumorSight cloud-based digital precision medicine platform.

FDA clearance came just days after the company inked a partnership with Mayo Clinic to develop precision medicine solutions.

The TumorSight platform takes a patient’s standard-of-care imaging to build a custom 3D model of their tumor. The tool provides 3D spatial visualizations of breast cancer to support more effective planning and consultations. SimBioSys said it gives clinicians and patients a more comprehensive understanding of their cancer and the potential options available.

Additionally, the TumorSight application provides insights like tumor volume, tumor-to-breast volume and tumor distance to key anatomical structures. It quantifies key metrics required in treatment planning.

SimBioSys also plans to expand the TumorSight platform and incorporate a suite of innovative tools. Those tools could extend to surgical plan…

SimBioSys, Mayo Clinic partner on AI-powered tech for breast cancer patients

SimBioSys announced today that it entered into a strategic collaboration with Mayo Clinic to develop digital precision medicine solutions.

The collaboration aims to develop cloud-based clinical software to support end-to-end decision-making for early-stage breast cancer patients. This includes individualized surgical planning, treatment, drug selection and risk stratification.

As part of the collaboration, SimBioSys has had access to and has analyzed data from patients participating in the Mayo Clinic-led BEAUTY clinical trial. The company uses AI and data science to unlock spatial biophysical insights to help clinicians tailor treatment plans for each patient.

SimBioSys plans to perform simulations using previously acquired data. While validating the platform’s predictive accuracy, it also expects to perform in-silico scenario analysis guided by the Mayo team.

The company offers its TumorSight cloud-based platform for use during the treatme…

SimBioSys secures $15 million in Series A funding for computational oncology software

The developer of a cloud-based application for oncology care and research, SimBioSys, has raised $15 million in Series A funding. Genoa Ventures and Northpond Ventures led the funding round, which also involved AV8 Ventures, Heritage Medical Group, and Mayo Clinic.

SimBioSys also announced that existing investors and its founders participated in the financing, raising a total of $21 million.

The company plans on using the funds for the development and commercialization of its TumorScope software platform. In particular, the company plans on using the funding to digitize and model treatment options for a number of solid tumors, including in breast cancer.

TumorScope is a cloud-based application that virtualizes cancer in three dimensions. The company reports that it can accurately simulate how a patient’s tumor will respond to a variety of therapies following diagnosis. “Simulating a response before prescribing treatment is a significant stride in p…